导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.51% | 1241/4773 |
| 近一周 | -1.02% | 1526/5465 |
| 近一月 | -3.45% | 2516/5421 |
| 近一季 | -7.69% | 2931/5231 |
| 近半年 | -3.21% | 2426/4920 |
| 近一年 | 9.56% | 1186/4394 |
| 近两年 | 76.97% | 890/2954 |
| 近三年 | 42.28% | 712/2253 |
| 成立以来 | 148.21% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.82% 1171/4961 |
19.21% 1313/5312 |
- - |
- - |
| 2025 | 31.34% 1245/4813 |
2.53% 1344/3635 |
2.08% 1891/4076 |
24.38% 1475/4524 |
0.89% 1686/4813 |
| 2024 | 7.53% 1649/3463 |
-2.65% 1399/2808 |
-5.06% 1629/3014 |
15.73% 1640/3129 |
0.52% 1201/3463 |
| 2023 | -6.08% 811/2656 |
7.44% 573/2280 |
-3.93% 972/2385 |
-4.92% 1258/2515 |
-4.31% 958/2655 |
| 2022 | -16.98% 539/2207 |
-12.90% 665/1919 |
2.96% 1235/2016 |
-9.82% 313/2113 |
2.65% 872/2208 |
| 2021 | 20.81% 175/1822 |
-0.94% 409/1255 |
11.16% 392/1330 |
5.82% 255/1466 |
3.68% 403/1822 |
| 2020 | 35.54% 411/1250 |
-2.55% 268/1028 |
19.30% 302/1067 |
11.10% 479/1164 |
4.94% 822/1184 |
| 2019 | - - |
- - |
-9.58% 669/788 |
2.26% 311/850 |
6.54% 597/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华中证500指数(LOF)C VS. 长安沪深300非周期A(740101) |